sel24
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2017 (NCT03008187)
Timeline
Indications
Mechanism of action
- Serine/threonine-protein kinase PIM1INHIBITOR
PIM1 inhibitor
FLT3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- sel24
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06534437 | Phase 2 | Nov 30, 2024 | Menarini Group, Selvita S.A. |
| NCT03008187 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2017 | Selvita S.A., Theradex, University of Texas at Houston |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Selvita S.A. | For profit | 2 | 2 | 1 | 2017 |
| Menarini Group | For profit | 1 | 0 | 1 | 2024 |
| Theradex | For profit | 1 | 0 | 1 | 2017 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2017 |
4 organizations
Page 1 / 1